Morgan Stanley noted that an abstract for Eli Lilly's extension trial for its solanezumab drug for Alzheimer's disease will be available to registered attendees of the Alzheimer's Association International Conference tomorrow, June 12, ahead of the presentation at the conference on July 22. The firm noted that 1,235 patients were treated with solanezumab in the extension for 104 weeks and that it hopes to see a benefit in patients who originally received placebo that is comparable to the benefit shown in patients who received the drug in earlier trials. Morgan Stanley has Overweight rating on Lilly shares.